Clinical Trial Update: Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating different doses of dalpicicl in combination with letrozole as first-line therapy for hormone receptor-positive, HER2-negative ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Advanced Breast Cancer

Drugs mentioned

• Dalpicicl (dalpicicl)
• Letrozole (letrozole)

Snippet

Sponsor: wanghaibo | Conditions: HR Positive HER2 Negative Advanced Breast Cancer | Phase 2 | Status: RECRUITING